Zoetis Inc. (NYSE: ZTS)

Zoetis Inc., a prominent player in the animal health industry, operates under the stock symbol ZTS. The company is deeply invested in the research, development, production, and commercialization of medicines, vaccines, diagnostic products, and services for companion animals and livestock. With a diverse business model, Zoetis caters to eight core species, including dogs, cats, horses, cattle, swine, poultry, fish, and sheep, across seven major product categories.

Zoetis' revenue is primarily generated through the sale of its products, which span across eight categories: parasiticides, vaccines, dermatology products, other pharmaceuticals, anti-infectives, animal health diagnostics, and medicated feed additives. The company's primary products include Simparica, Simparica Trio, Apoquel, Cytopoint, ProHeart, and Revolution, among others. These products are marketed through a network of sales representatives, technical and veterinary operations specialists, and distributors.

In the U.S., Zoetis' largest market, the company generated $4,555 million in revenue in 2023, accounting for 53% of its total revenue. The U.S. segment boasts a diverse product portfolio for both companion animals and livestock customers. Companion animal products, such as Apoquel and Simparica, constitute approximately 65% of revenue, while livestock products, including vaccines and anti-infectives, account for approximately 34%.

Internationally, Zoetis operates in over 100 countries, with a direct presence in approximately 45 countries. The international segment contributed $3,911 million to the company's total revenue in 2023, representing 46% of the total. However, these international businesses are subject to various risks, including currency fluctuations, capital and exchange control regulations, expropriation, and other restrictive government actions.

Zoetis' product portfolio is characterized by a range of innovative solutions that cater to diverse animal health needs. Key products include Simparica and Simparica Trio, monthly chewable tablets for dogs to control fleas and ticks; Apoquel and Apoquel Chewable, selective inhibitors of the Janus Kinase 1 enzyme for the control of pruritus associated with allergic dermatitis and atopic dermatitis; Cytopoint, an injectable to help reduce the clinical signs of atopic dermatitis in dogs; ProHeart, a once-yearly injection to prevent heartworm disease in dogs; Revolution, an antiparasitic for protection against fleas, heartworm disease, and ear mites in cats and dogs; Cerenia, a medication for the prevention and treatment of acute vomiting in dogs and cats; Librela, an injectable monthly antibody therapy to alleviate osteoarthritis pain in dogs and cats; and Rimadyl, a medication for the relief of pain and inflammation associated with osteoarthritis and postoperative pain in dogs.

Zoetis' competitive advantages stem from its strong brand portfolio, innovative products, and global presence. The company's products are widely recognized and respected in the animal health industry, and its research and development efforts are focused on developing new and innovative products to address emerging animal health needs.

Zoetis' customers include veterinarians, livestock producers, and pet owners. The company primarily sells its products to veterinarians or third-party veterinary distributors, who then sell the products to pet owners. In certain markets, Zoetis also sells certain products through retail and e-commerce outlets.